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Abstract
Background: Imatinib mesylate has been used for the treatment of unresectable or metastatic gastrointestinal
stromal tumors (GIST). The current recommended dose of imatinib is 400 mg/day that is increased to 800 mg/day
in cases with disease progression. However, imatinib can be associated with diverse adverse events, which has
limited its use. We report a case of severe adverse skin reactions with neutropenic fever during imatinib treatment
in a patient with GIST.
Case presentation: A 71-year-old man was admitted with a one month history of epigastric pain and a palpable
mass in the right upper quadrant. An abdominal CT scan revealed a 20 × 19 cm intraabdominal mass with tumor
invasion into the peritoneum. Needle biopsy was performed and the results showed spindle shaped tumor cells
that were positive for c-KIT. The patient was diagnosed with unresectable GIST. Imatinib 400 mg/day was started.
The patient tolerated the first eight weeks of treatment. However, about three months later, the patient developed
a grade 4 febrile neutropenia and a grade 3 exfoliative skin rash. The patient recovered from this serious adverse
events after discontinuation of imatinib with supportive care. However, the skin lesions recurred whenever the
patient received imatinib over 100 mg/day. Therefore, imatinib 100 mg/day was maintained. Despite the low dose
imatinib, follow up CT showed a marked partial response without grade 3 or 4 toxicities.
Conclusion: The recommended dose of imatinib for the treatment of GIST is 400 mg/day but patients at risk for
adverse drug reaction may benefit from lower doses. Individualized treatment is needed for such patients, and we
may also try sunitinib as a alternative drug.
Background
Imatinib mesylate is a selective tyrosine kinase inhibitor.
It has become the gold standard treatment for unresect-
able or metastatic gastrointestinal stromal tumors
(GIST). It has inhibitory activity against, BCR-ABL,
c-KIT, and PDGFR [1,2]. The most common adverse
events associated with imatinib include edema that is
most frequently periorbital, nausea, diarrhea, muscle
cramps, fatigue, skin rash, headache, and abdominal
pain. Imatinib induced grade 3-4 neutropenia and skin
rash may occur in as many as 7.1% and 3.8% of GIST
patients, respectively [3,4]. The toxicities are generally
mild or moderate and of grade 1 or 2 severity (NCI-
CTC). Rarely, serious gastrointestinal or intraabdominal
hemorrhage can occur in patients with large, bulky
tumors [2,3]. Most cutaneous reactions are mild, how-
ever, severe reactions such as exfoliative dermatitis,
toxic epidermal necrolysis and Stevens Johnson syn-
drome can also occur [5]. Sunitinib has demonstrated
efficacy in treating patients with GIST who have experi-
enced disease progression on or intolerance to imatinib
[6]. However, due to the effectiveness of imatinib, imati-
nib may need to be used again in some patients despite
a history of severe reactions. We report a case of severe
adverse skin reactions with neutropenic fever during
imatinib treatment.
Case presentation
A 71-year-old man was admitted with a one month his-
tory of epigastric pain and a palpable mass in the right
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medical history. A CT scan of the abdomen showed a
20 × 19 cm intraabdominal mass with central necrosis
in the infra-hepatic space and tumor invasion into the
peritoneum (Figure 1). For a definitive diagnosis, ultra-
sound guided needle biopsy was performed. The results
showed spindle shaped tumor cells that were strongly
positive for c-KIT by CD 117 immunohistochemical
staining; other immunohistochemical staining was nega-
tive including actin, desmin, S-100 and CD 34 (Figures
2). The mitotic figures were >5/50 high power field.
Because the mass invaded the peritoneum, the patient
was diagnosed with unresectable GIST. Given this
diagnosis, treatment with imatinib at a dose of 400 mg
daily was started. The patient tolerated the first eight
weeks of treatment; the only toxicities were mild perior-
bital edema and pruritus. However, about three months
after beginning treatment, the patient developed mild
d i a r r h e a ,ag r a d e4f e b r i l en e u t r o p e n i a ,a n dag r a d e3
generalized erythematous maculopapular rash covered
by whitish dry scales affecting the face, trunk and upper
l i m b s( F i g u r e s3 ) .T h ep a t i e n td i dn o td e v e l o p e da n y
other lymphadenopathy and there were no oral mucosal
lesions. The patient was admitted to the hospital and
reported general weakness, loss of appetite, and visual
problems including conjunctival suffusion and itching of
both eyes. The periorbital edema was so severe that he
could not open his eyes. The vital signs showed a high
fever (temperature of 38.6°C, blood pressure 120/70
mmHg, heart rate 72/minute, and respiratory rate 18/
minute). Laboratory examination revealed neutropenia,
eosinophilila and a mild anemia, that is, white blood cell
count 2.5 × 10
9/L (reference value 4-10.8 × 10
9/L),
absolute neutrophil count 0.15 × 10
9/L (reference value
>1 . 5×1 0
9/L), eosinophil count 1.25 × 10
9/L (percent
eosinophil 50%) (reference value percent eosinophil
0-7%), hemoglobin 10.2 g/dl (12-18 g/dl), platelet count
Figure 1 Initial CT scan showed a 20 × 19 cm intraabdominal
mass with central necrosis in the infra-hepatic space and
tumor invasion into the peritoneum.
Figure 2 Microscopic finding of the intraabdominal GIST
demonstrating spindle cells (H&E; magnification, × 20). The
tumor cells were strongly positive for c-KIT (small picture,
magnification, × 10).
Figure 3 The patient had marked periorbital edema, and an
erythematous maculopapular rash covered by whitish dry
scales affecting the face.
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9/L (130-450 × 10
9/L). Other blood chemistries
revealed alkaline phosphatase 386 IU/L (39-117 IU/L),
aspartate aminotransferase 66 IU/L (7-38 IU/L), alanine
aminotransferase 161 IU/L (4-43 IU/L), lactate dehydro-
genase 498 IU/L (218-472 IU/L), total bilirubin 3.9 mg/
dL (0.35-1.3 mg/dL), blood urea nitrogen 29 mg/dL
(8-23 mg/dL), creatinine 1.4 mg/dL (0.5-1.3 mg/dL).
Mild hepatic and renal dysfunction was suspected. The
patient was taking no other medication except for imati-
nib. Therefore, administration of imatinib was promptly
discontinued, and a dermatological consultation was
obtained.
The cutaneous findings were compatible with the
diagnosis of an exfoliative dermatitis due to imatinib.
The patient was managed with hydration and parenteral
injections of a third generation cephalosporin as well as
granulocyte colony stimulating factor. For the skin
lesion management, systemic steroids (oral prednisone
30 mg/day) with topical steroid and emollient cream
were provided. The patient recovered from the febrile
neutropenia, and the eosinophil count normalized sub-
sequently. The results of blood culture was negative and
there were no infection foci. The skin lesions gradually
improved with a reduction of the extension and severity
of the erythema and scales. Further dermatological treat-
ment was continued and one month later the rashes
completely resolved with hyperpigmented areas
remaining.
After the skin lesions improved, that is, one month later
after stopping the imatinib, the drug was started at a dose
of 100 mg every other day for 1 week without any compli-
cations. The dose was increased to 100 mg daily and the
patient tolerated this dose. Subsequently the imatinib was
increased to 200 mg daily, and then the periorbital edema
and exfoliative skin lesions recurred on the forth day after
the dose increase. Laboratory examination also showed
increased liver enzyme, AST 89 IU/L, ALT 133 IU/L, and
LDH 941 IU/L. We tried several times to increase the
dose of imatinib. However, severe exfoliative dermatitis,
periorbital edema, and elevation of liver enzymes devel-
oped each time. The combined steroid therapy was some-
what effective, but the exfoliative skin lesions progressed.
After complete recovery, the imatinib was started again at
a dose of 100 mg daily and this was maintained. Serial CT
was performed to evaluate the tumor response. The first
follow up CT was performed three months after starting
the imatinib medication. The CT showed a partial
response according to RECIST criteria, that is, the tumor
decreased from 20 × 19 cm to 14 × 8 cm. At the second
follow up CT after the patient received imatinib for about
3 weeks, during the prior 3 months due to severe hyper-
sensivity reaction the CT showed a decrease in the tumor.
Therefore, the patient has been maintained on imatinib
100 mg daily with CT follow up every 3-months. Despite
the low dose imatinib, the last follow up CT revealed a
prolonged partial response, and the tumor decreased to
8 × 8 cm (Figure 4).
Conclusion
Gastrointestinal stromal tumors (GIST) are a subtype of
sarcomas that have a unique natural history. Imatinib
mesylate, a selective tyrosine kinase inhibitor, has
become the gold standard for the treatment of unresect-
able or metastatic GIST [1].
Skin rashes are a well recognized side effect of imati-
nib treatment. In most cases, the lesions are mild, self
limiting, and easily managed with anti-histamines or
topical steroids, whereas a short course of oral steroids
can be used to treat more severe cases [7]. Grade 3 or 4
skin rashes may occur in 3.8% of patients. In some
patients, severe rashes can develop with desquamative
components, including a report of Steven-Johnson syn-
drome [8-10]. In such cases, immediate discontinuation
of therapy and systemic steroids are indicated. Severe
skin lesions that were resistant to supportive measures
have been the most frequent cause for permanent dis-
continuation of imatinib therapy. However, the fre-
quency of this event is small (<1% of all patients) [7].
Standard management of drug induced skin rashes
usually includes discontinuation of the suspected drug
and avoidance of further exposure to this drug in the
future. However, due to the effectiveness of imatinib,
most oncologists try to maintain or reinitiate treatment
with imatinib. To overcome severe skin reactions, sev-
eral methods such as temporary discontinuation of ima-
tinib treatment, once weekly dosing, a lower daily dose
with or without a short course of an oral corticosteroid,
and gradual dose escalation, have been reported
[11-13,9,14].
Figure 4 Last follow up CT scan revealed a partial response.
The tumor decreased to 8 × 8 cm.
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treatment was initiated and the skin rashes resolved gra-
dually over one month. We started the imatinib again,
but we could not increase the dose above 100 mg/day
due to recurrence of the lesions. However, even with
the low dose of imatinib, 100 mg/day, follow up CT
demonstrated a decreased tumor mass. We could also
try sunitinib which had demonstrated efficacy in treating
patients with GIST who have experienced disease pro-
gression on or intolerance to imatinib [6]. However, the
patient had good tumor response to imatinib, therefore
we tried to maintain the imatinib.
Several studies have reported a dose related skin toxi-
city of imatinib, indicating a pharmacological effect of
imatinib. This case can also mainly be related to the
pharmacological effect of imatinib, but the delayed type
hypersensitivity might be involved in some aspects like
other skin rashes considering eosinophilia and pruritus
[15-17]. The cause of the skin rashes is unclear. How-
ever, the platelet derived growth factor receptor is found
abundantly in keratinocytes, and its inhibition by imati-
n i bm a yp l a yar o l ei nt h eo c c u r r e n c eo ft h i sr e a c t i o n
[14]. Other investigators have proposed that certain skin
reactions may result from an inhibition of KIT, found in
basal cells [7,14,18]. However, it is unclear why these
severe skin rashes develop in only a minority of patients.
Recently, Demetri et al. suggested that imatinib trough
levels at steady state were associated with a clinical ben-
efit [19]. According to this report, patients with an ima-
tinib trough concentration, below 1,100 ng/ml, showed
a shorter time to progression (11.3 months) and lower
rate of clinical benefit. In our case, the trough concen-
tration at steady state was 331 ng/ml. It remains to be
seen whether the tumor will progress earlier or maintain
a partial response. However, to date, the patient has
showed a good tumor response over 14 months. The
current recommended daily dose of imatinib is 400 mg,
however, patients at risk for adverse drug reactions may
b e n e f i tf r o ml o w e rd o s e s .I n dividualized treatment is
needed for such patients, and we may also try sunitinib
as a alternative drug.
In conclusion, we describe a patient with an intraab-
dominal GIST that had a good tumor response,
although we could not increase the dose of imatinib
above 100 mg/day due to severe adverse skin reactions.
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